A simple 3-step model of “dynamic individualized dosing” in the early phase of critical illness, taking into account the compensation for losses of antibiotics associated with pharmacokinetics (PK) changes and/or more resistant bacteria (higher minimal inhibitory concentration [MIC] values). In high-inoculum infections, loading doses followed by high maintenance doses for the shortest duration possible will likely optimize clinical outcome and minimize the risk of resistance during treatment. In absence of therapeutic drug monitoring (TDM) and dosing software, dose adjustments should be based on daily assessment of PK-pharmacodynamics parameters to optimize dose and clinical/microbiological outcome. EMCO, extracorporeal membrane oxygenation; MRSA, methicillin-resistant Staphylococcus aureus.